- Full name: Nicotinamide Adenine Dinucleotide (oxidised form)
- Molecular weight: 663.43 Da
- CAS: 53-84-9
- Primary roles: Redox cofactor, sirtuin substrate, PARP cofactor
- Age-related decline: ~50% reduction from young adult to elderly tissue levels
- Key enzymes: SIRT1–7, PARP1–2, CD38, NAMPT (rate-limiting biosynthesis)
01 What Is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in cellular biology. Found in every living cell, NAD+ participates in over 500 enzymatic reactions and exists in two interconvertible forms: the oxidised form (NAD+) and reduced form (NADH). The ratio of NAD+ to NADH is a key indicator of cellular redox state and metabolic health.
NAD+ serves three primary biological functions:
- Redox reactions — accepts and donates electrons in glycolysis, the TCA cycle, and oxidative phosphorylation, enabling ATP production
- Sirtuin co-substrate — required for sirtuin deacylase activity, linking NAD+ availability directly to epigenetic regulation and stress responses
- PARP substrate — consumed by poly(ADP-ribose) polymerases during DNA damage repair, creating a direct link between genomic integrity and NAD+ levels
The convergence of these roles at the intersection of energy metabolism, DNA maintenance, and gene regulation makes NAD+ uniquely central to the biology of aging.
02 Aging & NAD+ Decline
One of the most robust findings in aging biology is the progressive decline of NAD+ levels across virtually every tissue studied. Hippocampal, hepatic, skeletal muscle, and dermal NAD+ levels all fall approximately 40–60% between young adulthood and late life in rodent models — with human tissue data broadly corroborating this trajectory.
Why Does NAD+ Fall?
Three primary mechanisms drive the age-related decline:
- PARP hyperactivation — as DNA damage accumulates with age, PARP enzymes consume increasing amounts of NAD+ for repair reactions. Each PARP activation event can consume hundreds of NAD+ molecules.
- CD38 upregulation — CD38 is an ectoenzyme that cleaves NAD+ as part of calcium signalling. CD38 expression increases significantly with age and inflammation ("inflammaging"), making it a major contributor to NAD+ depletion in aged tissue.
- NAMPT decline — NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the NAD+ salvage pathway, converting nicotinamide back to NMN → NAD+. NAMPT expression and activity decline with age, reducing the cell's capacity to recycle NAD+ precursors.
- Young adult (20–25): Baseline reference (100%)
- Middle age (45–50): ~60–70% of young adult levels
- Elderly (70+): ~40–50% of young adult levels
- Tissue most affected: Brain, skeletal muscle, liver, skin
03 Sirtuin Activation
Sirtuins are a family of seven NAD+-dependent protein deacylases (SIRT1–7) that function as master regulators of cellular stress responses and aging. They were first identified through lifespan extension studies in yeast and subsequently found to be broadly conserved across eukaryotes.
Key Sirtuins and Their Roles
| Sirtuin | Location | Primary Function |
|---|---|---|
| SIRT1 | Nucleus/cytoplasm | Gene silencing, metabolic regulation, inflammation control |
| SIRT2 | Cytoplasm | Cell cycle, microtubule regulation |
| SIRT3 | Mitochondria | Mitochondrial protein deacetylation, ROS control |
| SIRT4 | Mitochondria | Fatty acid oxidation regulation |
| SIRT5 | Mitochondria | Ammonia detoxification, metabolite modification |
| SIRT6 | Nucleus | DNA double-strand break repair, telomere maintenance |
| SIRT7 | Nucleus/nucleolus | rRNA transcription, DNA damage response |
Crucially, all seven sirtuins require NAD+ as a co-substrate. As NAD+ declines with age, sirtuin activity falls proportionally — creating a feed-forward loop where diminished sirtuin function accelerates the accumulation of cellular damage that further drives NAD+ depletion.
04 PARP & DNA Repair
PARP1 (poly(ADP-ribose) polymerase 1) is the primary DNA damage sensor in eukaryotic cells. When it detects single-strand or double-strand DNA breaks, it rapidly poly-ADP-ribosylates (PARylates) nearby proteins, creating a scaffold for DNA repair machinery recruitment. Each PARP1 activation event consumes 40–150 NAD+ molecules to generate PAR chains.
In young cells with intact genomes, PARP activation is episodic and NAD+ is rapidly resynthesised. In aged cells accumulating persistent DNA damage from oxidative stress, replication errors, and environmental insults, PARP is constitutively hyperactivated — creating a major drain on the NAD+ pool and competing directly with sirtuins for NAD+ availability.
This competition between PARP and sirtuins for a shrinking NAD+ pool is considered one of the central mechanisms connecting DNA damage accumulation to the epigenetic dysregulation and metabolic dysfunction of aging — as proposed in the Information Theory of Aging (Sinclair, 2019).
05 Mitochondrial Biogenesis
SIRT1 and SIRT3 activation downstream of NAD+ availability directly promotes mitochondrial biogenesis through deacetylation and activation of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) — the master regulator of mitochondrial biogenesis and energy metabolism.
PGC-1α activation drives:
- Formation of new mitochondria (mitochondrial biogenesis)
- Upregulation of mitochondrial oxidative phosphorylation genes
- Enhanced fatty acid oxidation capacity
- Improved antioxidant defence (SOD2, catalase)
NAD+ supplementation in aged rodent models has consistently restored PGC-1α activity and mitochondrial number/function in skeletal muscle, with behavioural correlates including improved exercise capacity and grip strength — two of the most clinically relevant markers of aging in humans.
06 NAD+ vs NMN vs NR
| Compound | Type | Oral Bioavailability | Route to NAD+ | Human Data |
|---|---|---|---|---|
| NAD+ | Direct coenzyme | Limited orally; good IV/subQ | Direct (connexin uptake / IV) | IV: yes; oral: limited |
| NMN | Precursor | Moderate (Slc12a8 transporter) | NMN → NAD+ (NMNAT) | Multiple RCTs |
| NR | Precursor | Good | NR → NMN → NAD+ | Multiple RCTs |
| Nicotinamide | Precursor | Good but SIRT-inhibiting at high dose | NAM → NMN → NAD+ (salvage) | Yes |
The key distinction: oral NAD+ is largely degraded in the gut and absorbed as precursors (NMN, NR). However, subcutaneous and intravenous NAD+ bypasses this barrier, delivering NAD+ directly to the bloodstream where it can be taken up by tissues — particularly relevant for acute high-dose research protocols.
07 Delivery Routes
NAD+ for research use is typically supplied as the disodium salt in lyophilised form. Reconstitution with sterile water produces a solution suitable for subcutaneous or intravenous administration in research settings. Stability of reconstituted NAD+ is limited — oxidation occurs rapidly at room temperature, and fresh preparation is recommended before each use.
Subcutaneous administration produces a slower, more sustained NAD+ plasma curve compared to IV bolus, potentially preferable for steady-state tissue delivery in chronic research protocols. Both routes significantly outperform oral NAD+ in terms of achieved plasma levels.
08 Frequently Asked Questions
What is NAD+?
A coenzyme present in all living cells, essential for energy metabolism, DNA repair, and sirtuin-mediated gene regulation. Its decline with age is implicated in multiple hallmarks of aging.
Why does NAD+ decline with age?
PARP hyperactivation (DNA damage repair), CD38 upregulation with inflammaging, and reduced NAMPT activity (rate-limiting biosynthesis enzyme) all contribute to a ~50% tissue NAD+ decline between young adulthood and old age.
What are sirtuins and how does NAD+ activate them?
Sirtuins (SIRT1–7) are NAD+-dependent enzymes that deacetylate histones and proteins, regulating gene expression, DNA repair, and mitochondrial function. They require NAD+ as a co-substrate — falling NAD+ directly reduces sirtuin activity.
What is the difference between NAD+, NMN, and NR?
NMN and NR are precursors converted to NAD+ intracellularly. Oral NAD+ is largely degraded before uptake; IV/subQ NAD+ bypasses this. All three can raise cellular NAD+ levels with different pharmacokinetic profiles.
Is IV NAD+ better than oral NMN?
IV/subQ NAD+ achieves significantly higher plasma levels than oral precursors. Whether this translates to superior clinical outcomes remains under investigation. For research purposes, route selection depends on the experimental design and tissue pharmacokinetics of interest.